Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

This study has been withdrawn prior to enrollment.
(Study stopped)
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT01260844
First received: December 14, 2010
Last updated: October 19, 2011
Last verified: May 2011
  Purpose

Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.


Condition Intervention Phase
Moderate to Severe Plaque Psoriasis
Drug: briakinumab
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metroprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Assessment of the drug-drug interaction potential of briakinumab (ABT-874) with cytochrome CYP 1A2. CYP2C9, CYP2C19, CYP2D6 and CYP3A4 in moderate to severe plaque psoriasis subjects [ Time Frame: 17 days ] [ Designated as safety issue: No ]
    CYP Substrate cocktail administed at Day -1 and day 14 and Briakinumab at Day 1


Secondary Outcome Measures:
  • No secondary outcomes are reported for this study [ Time Frame: No secondary outcomes are reported for this study ] [ Designated as safety issue: No ]
    No secondary outcomes are reported for this study


Estimated Enrollment: 12
Study Start Date: April 2011
Arms Assigned Interventions
Experimental: single dose of briakinumab
single dose briakinumab cocktail of CYP substrates
Drug: briakinumab
single dose briakinumab and 2 doses of CYP substrates
Other Name: ABT-874 Briakinumab

Detailed Description:

The study does involve 3 days confinement at the beginning of the trial and 4 days at the end of the trial. The trial duration is 17 days with 6 visits not including the confinement periods. The trial is being conducted in moderate to severe plaque psoriasis subjects. Serial blood samples will be taken after each doses of the CYP substrates are administered and blood samples will be collected for briakinumab PK and briakinumab ADA.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Male or female and age is between 18 and 55 years, inclusive.
  2. Clinical diagnosis of plaque psoriasis for at least 6 months as determined by subject's interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator.
  3. Moderate to severe plaque psoriasis defined by ≥ 10% Body Surface Area (BSA) involvement at the Screening visit and Day -2 visit.
  4. PGA of at least moderate (defined as a PGA of ≥3) disease at the Screening visit and Day -2 visit.
  5. Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray, and 12-lead electrocardiogram (ECG) performed at Screening.
  6. Females must have negative results on all pregnancy tests during the study.
  7. Body Mass Index (BMI) is between 18 to 29, inclusive.

Exclusion Criteria

  1. History of either Type 1 or 2 diabetes
  2. History of significant sensitivity to any drug
  3. History of drug or alcohol abuse within 6 months prior to screening
  4. Receipt of any investigational product within 1 month prior to day -2 , or current participation in any clinical study receiving any study drug or device
  5. Use of known CYP inhibitors (e.g., ketoconazole, clotrimazole) or inducers (e.g., dexamethasone, phenytoin, rifampin, carbamazepine) within 1 month prior to Day -2
  6. Use of known CYP substrates, (including hormonal contraception), within 1 month prior to Study Day-2. See Appendix E for List of Cytochrome P450 (CYP) Medications for the Treatment of Hypertension and Dyslipidemia
  7. Receipt of any vaccine within 3 months prior to study drug administration
  8. Subject has received vaccination with Bacille Calmette-Guérin (BCG)
  9. Previous exposure to systemic anti-IL-12/23 therapy, including briakinumab (ABT-874) or ustekinumab.
  10. Cannot discontinue systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis, during the study:

    • Non-biologic systemic (investigational or marketed) therapies must be discontinued at least 1 month prior to the Day-2
    • Biologic (investigational or marketed) therapies must be discontinued at least 12 weeks prior to Day-2
  11. Subjects that must use topical therapies for the treatment of psoriasis such as corticosteroids, vitamin D analogs, or retinoids during the study. Subjects are allowed to use:

    • Shampoos that contain no corticosteroid;
    • Bland (without beta or alpha hydroxy acids) emollients;
    • Low potency (Class VI or Class VII) topical corticosteroids on the palms, soles, face, inframammary area, and groin only. See Appendix F for a Listing of Examples of Class VI and VII Topical Corticosteroids
  12. Cannot avoid PUVA phototherapy during the study.
  13. Subject is taking or requires oral, injectable or inhaled corticosteroids during the study.
  14. Use of herbal or dietary supplements, such as St. John's Wort, within 1 month prior to Day -2 or 10 half lives whichever is longer.
  15. Use of caffeine and/or theobromine (coffee, chocolate, tea, cola drinks, mountain dew etc.) within three days prior to Day-2 and Day 12.
  16. Consumption of orange, grapefruit or orange or grapefruit products (juices), broccoli, brussels sprouts, or charcoal grilled meats within three days prior to Day-2 and Day 12
  17. Consumption of alcohol within the 48 hours prior to Day-2 and Day 12.
  18. Use of tobacco or nicotine-containing products within the 6-month period preceding Day-2.
  19. Positive screen for drugs of abuse, alcohol or cotinine
  20. Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study or in the 60 days after receiving the single dose of study drug
  21. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening, and the results will be maintained and communicated to the subjects confidentially by the study site.
  22. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption
  23. Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks Day-2.
  24. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis.
  25. Poorly controlled medical condition, such as documented history of recurrent infections, unstable ischemic heart disease, congestive heart failure, recent cerebrovascular accidents and any other condition, or an unstable psychiatric condition which, in the opinion of the investigator and/or Abbott's Medical Monitor, would put the subject at risk by participation in the study
  26. Subject has infection or risk factors for severe infections, for example:

    • Active tuberculous disease;
    • Evidence of latent tuberculosis (TB) infection demonstrated by a positive result of their Purified Protein Derivative (PPD) skin test
    • Subject is taking TB prophylaxis medication
    • Any other significant infection requiring hospitalization or intravenous (IV) antibiotics in the month prior to Day -2;
    • Infection requiring treatment with antibiotics in the month prior to Day -2
  27. History of atherosclerotic cardiovascular disease as manifested by any of the following:
  28. History of malignancies other than successfully treated basal cell carcinoma, non-metastatic cutaneous squamous cell carcinoma or cervical carcinoma in situ
  29. Exacerbation of asthma requiring hospitalization in the 10 years prior to screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01260844

Sponsors and Collaborators
Abbott
Investigators
Study Director: David A Williams, MD Abbott
  More Information

No publications provided

Responsible Party: Abbott
ClinicalTrials.gov Identifier: NCT01260844     History of Changes
Other Study ID Numbers: M12-160
Study First Received: December 14, 2010
Last Updated: October 19, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014